STAT Plus: Biomarin, Gilead drug rejections don’t signal a change in attitude at the FDA
It’s tempting to interpret the Food and Drug Administration’s surprise rejections of drugs from Gilead Sciences and Biomarin Pharmaceuticals this week as an agency-wide sentiment downshift, raising concerns that fewer new medicines will reach the market.
Don’t make that mistake.
Continue to STAT Plus to read the full story…
